NICE U-turn for Kisqali in breast cancer
admin 17th July 2019 Uncategorised 0NICE has recommended Novartis’ Kisqali just three months after its initial rejection. More: NICE U-turn for Kisqali in breast cancer Source: News
read moreNICE has recommended Novartis’ Kisqali just three months after its initial rejection. More: NICE U-turn for Kisqali in breast cancer Source: News
read moreThe ‘toolkit’, will be available to help companies implement the FAIR guiding principles for data management and stewardship. More: Pistoia Alliance launches FAIR implementation ‘toolkit’ Source: News
read moreSeveral Johnson & Johnson drugs are contributing strong growth, but some struggling medicines weighed on the company’s overall performance. More: Earnings bulletin: Johnson & Johnson's second quarter of 2019 Source: fierce
read moreCalled a “kingpin” and accused of launching a “multibillion brainwashing campaign” to sell its opioid drugs, Johnson & Johnson has run the gantlet in its court battle with the state of Oklahoma. But name-calling aside, should J&J be held responsible
read moreJohnson & Johnson’s pharma unit is still churning out growth, partly because of outperforming new launches like cancer med Darzalex. But execs had to explain away some disappointing results for blockbusters Zytiga and Xarelto. More: J&J execs have plenty to
read moreNovartis’ plan to launch over 10 potential blockbuster drugs or new indications by 2021 is quickly unfolding. The FDA has accepted a biologics application for the pharma giant’s sickle cell disease candidate crizanlizumab. More: Novartis’ crizanlizumab wins speedy FDA review, putting
read more© 1994 - 2024 B.M. Pharmaceuticals